Exhale

The official blog of the Lung Institute.

Lung Institute White Paper Reveals Evidence of Pulmonary Function Improvement from Stem Cell Therapy

21 Jan 2016
| Under Press | Posted by | 6 Comments
Lung Institute White Paper

A new white paper released by the Lung Institute shows an increase of 10 percent or more in pulmonary function for 48 percent of patients tested after receiving stem cell therapy for COPD, with an overall average increase of 16 percent.

TAMPA, Fla. – January 26, 2016: Lung Institute doctor Jack Coleman, Jr., M.D. recently released a white paper showing evidence that stem cell therapy for lung diseases improves most patients’ quality of life scores and, in some cases, pulmonary function. The paper outlines a study that was conducted following 100 patients who received autologous stem cell therapy for chronic obstructive pulmonary disease (COPD).

“COPD is currently the third leading cause of death in the United States, and we’re giving our patients an alternative option that doesn’t just mask the symptoms.”

COPD and Stem Cell Therapy“Although research on the use of autologous stem cells is still in its early stages, it has shown substantive progress in treating patients with few, if any, adverse effects,” Dr. Coleman stated. “COPD is currently the third leading cause of death in the United States, and we’re giving our patients an alternative option that doesn’t just mask the symptoms.”

Coleman’s white paper summarizes the results of a study where approximately 100 patients with lung diseases were treated using stem cell therapy. Three months after treatment, 84 percent of patients reported an improved quality of life. The average improvement was 35 percent. Additionally, 25 of the patients in this study group were tested for pulmonary function. 48 percent of those 25 patients saw an increase in pulmonary function of over 10 percent, with the average rate of improvement at 16 percent. This sampling of patients represents one of the largest study groups tested in regard to how stem cells affect those with lung diseases.

Lung diseases are degenerative, meaning pulmonary function is expected to decline, making an increase in pulmonary function even more noteworthy. Advancements such as this are why the Vatican hosts an annual conference on regenerative medicine and why the White House recently passed a bill approving stem cell research funding.

Supporters like the White House and Vatican are helping increase awareness as to all of the benefits of regenerative cellular therapy. In an article published on ChristianNewsWire, U.S. Rep. Chris Smith recently stated, “It remains one of the best kept secrets in America that umbilical cord blood stem cells and adult stem cells in general are curing people of a myriad of terrible conditions and diseases in adults as well as children.”

About the Lung Institute 

The Lung Institute, founded in 2013, is a leading medical provider of regenerative cellular therapy for lung diseases such as chronic obstructive pulmonary disease (COPD), pulmonary fibrosis and interstitial lung disease in the United States. Based in Tampa, Fla., the Lung Institute currently has clinics in Nashville, Tenn., Scottsdale, Ariz., and Pittsburgh, Pa., with plans to open three new locations in 2016. To date the organization has treated over 1,500 patients, helping them breathe easier in their fight against lung disease. For more information, please visit www.lunginstitute.com or call (800) 729-3065.

6 Comments

  1. PB

    4 days ago

    Dear Shafi,

    Thanks for your comment. In compliance with articles 1271.10 and 1271.15 of the FDA’s regulations on human cells, tissues, and cellular and tissue based products (HCT/Ps), the Lung Institute’s use of stem cell therapy for the treatment of chronic lung disease currently falls under exemption status and does not require further regulation or approval by the FDA. If you would like to read more about the FDA and stem cells, click here. We’re happy to answer your questions about stem cell treatment for chronic lung diseases, so feel free to contact us at (855) 313-1149 to speak one-on-one with a patient coordinator. We look forward to hearing from you soon.

    Kind Regards,

    The Lung Institute

  2. Shafi

    2 weeks ago

    I am studying different option for treatment is this
    Treatment is FDA approved.

  3. Pingback: Lung Institute White Paper Reveals Evidence of Pulmonary Function Improvement from Stem Cell Therapy |

  4. PB

    9 months ago

    Dear Piet,

    Thank you for your comment. The Lung Institute has published a white paper about our findings. To read our white paper, click here. Also, if you’re interested in learning more about stem cell treatment options, our qualified patient coordinators would be happy to speak with you. Feel free to contact us at (855) 313-1149.

    Best Regards,

    The Lung Institute

  5. Piet Brons

    9 months ago

    In Europe Stem Cell Therapy treatment of COPD is considered false and not giving substantial results by for instance Netherlands Respiratory Society. Do you have any scientific research that proves your claims that Stem Cell Therapy treatment of COPD is working and can you publish it for example on this site?
    That the White House and the Vatican supports you, is no proof and is not build on published scientific research!

  6. Pingback: Lung Institute White Paper Reveals Evidence of Pulmonary Function Improvement from Stem Cell Therapy | Park Avenue Stem Cell

Your Comment

Your email address will not be published.



* All treatments performed at Lung Institute utilize autologous stem cells, meaning those derived from a patient's own body. No fetal or embryonic stem cells are utilized in Lung Institute's procedures. Lung Institute aims to improve patients' quality of life and help them breathe easier through the use of autologous stem cell therapy. To learn more about how stem cells work for lung disease, click here.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

Under current FDA guidelines and regulations 1271.10 and 1271.15, the Lung Institute complies with all necessary requirements for operation. Any individual who accesses Lung Institute's website for information is encouraged to speak with his or her primary physician for treatment suggestions and conclusive evidence. All information on this site should be used for educational and informational use only.